Tumor Targeting via Sialic Acid
[68Ga]DOTA-en-pba as a New Tool for Molecular Imaging of Cancer with PET
Charalambos Tsoukalas (National Centre for Scientific Research Demokritos)
Simonetta Geninatti-Crich (University of Turin)
Anastasios Gaitanis (Biomedical Research Foundation of the Academy of Athens)
Theodoros Tsotakos (National Centre for Scientific Research Demokritos)
Maria Paravatou-Petsotas (National Centre for Scientific Research Demokritos)
Silvio Aime (University of Turin)
Rogelio Jiménez-Juárez (National Polytechnic Institute)
Constantinos D. Anagnostopoulos (Biomedical Research Foundation of the Academy of Athens)
Kristina Djanashvili (TU Delft - Applied Sciences)
Penelope Bouziotis (National Centre for Scientific Research Demokritos)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Purpose: The aim of this study was to demonstrate the potential of Ga-68-labeled macrocycle (DOTA-en-pba) conjugated with phenylboronic vector for tumor recognition by positron emission tomography (PET), based on targeting of the overexpressed sialic acid (Sia). Procedures: The imaging reporter DOTA-en-pba was synthesized and labeled with Ga-68 at high efficiency. Cell binding assay on Mel-C and B16-F10 melanoma cells was used to evaluate melanin production and Sia overexpression to determine the best model for demonstrating the capability of [68Ga]DOTA-en-pba to recognize tumors. The in vivo PET imaging was done with B16-F10 tumor-bearing SCID mice injected with [68Ga]DOTA-en-pba intravenously. Tumor, blood, and urine metabolites were assessed to evaluate the presence of a targeting agent. Results: The affinity of [68Ga]DOTA-en-pba to Sia was demonstrated on B16-F10 melanoma cells, after the production of melanin as well as Sia overexpression was proved to be up to four times higher in this cell line compared to that in Mel-C cells. Biodistribution studies in B16-F10 tumor-bearing SCID mice showed blood clearance at the time points studied, while uptake in the tumor peaked at 60 min post-injection (6.36 ± 2.41 % ID/g). The acquired PET images were in accordance with the ex vivo biodistribution results. Metabolite assessment on tumor, blood, and urine samples showed that [68Ga]DOTA-en-pba remains unmetabolized up to at least 60 min post-injection. Conclusions: Our work is the first attempt for in vivo imaging of cancer by targeting overexpression of sialic acid on cancer cells with a radiotracer in PET.